Literature DB >> 30378088

Is the Drug Burden Index Related to Declining Functional Status at Follow-up in Community-Dwelling Seniors Consulting for Minor Injuries? Results from the Canadian Emergency Team Initiative Cohort Study.

Edeltraut Kröger1,2,3, Marilyn Simard4,5, Marie-Josée Sirois4,5,6, Marianne Giroux4,6, Caroline Sirois4,5,6, Lisa Kouladjian-O'Donnell7,8, Emily Reeve7,8, Sarah Hilmer7,8, Pierre-Hugues Carmichael4,6, Marcel Émond4,5,6.   

Abstract

BACKGROUND: The Canadian Emergency Team Initiative (CETI) cohort showed that minor injuries like sprained ankles or small fractures trigger a downward spiral of functional decline in 16% of independent seniors up to 6 months post-injury. Such seniors frequently receive medications with sedative or anticholinergic properties. The Drug Burden Index (DBI), which summarises the drug burden of these specific medications, has been associated with decreased physical and cognitive functioning in previous research.
OBJECTIVES: We aimed to assess the contribution of the DBI to functional decline in the CETI cohort.
METHODS: CETI participants were assessed physically and cognitively at baseline during their consultations at emergency departments (EDs) for their injuries and up to 6 months thereafter. The medication data were used to calculate baseline DBI and functional status was measured with the Older Americans Resources and Services (OARS) scale. Multivariate linear regression models assessed the association between baseline DBI and functional status at 6 months, adjusting for age, sex, baseline OARS, frailty level, comorbidity count, and mild cognitive impairment.
RESULTS: The mean age of the 846 participants was 77 years and their mean DBI at baseline was 0.24. Complete follow-up data at 3 or 6 months was available for 718 participants among whom a higher DBI at the time of injury contributed to a lower functional status at 6 months. Each additional point in the DBI lead to a loss of 0.5 points on the OARS functional scale, p < 0.001. Among those with a DBI ≥ 1, 27.4% were considered 'patients who decline' at 3 or 6 months' follow-up, compared with 16.0% of those with a DBI of 0 (p = 0.06).
CONCLUSIONS: ED visits are considered missed opportunities for optimal care interventions in seniors; Identifying their DBI and adjusting treatment accordingly may help limit functional decline in those at risk after minor injury.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30378088     DOI: 10.1007/s40266-018-0604-9

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  70 in total

1.  Adverse drug events in cognitively impaired elderly patients.

Authors:  Hooman Ganjavi; Nathan Herrmann; Paula A Rochon; Papita Sharma; Monica Lee; Daniel Cassel; Morris Freedman; Sandra E Black; Krista L Lanctôt
Journal:  Dement Geriatr Cogn Disord       Date:  2007-03-29       Impact factor: 2.959

2.  Cumulative incidence of functional decline after minor injuries in previously independent older Canadian individuals in the emergency department.

Authors:  Marie-Josée Sirois; Marcel Émond; Marie-Christine Ouellet; Jeffrey Perry; Raoul Daoust; Jacques Morin; Clermont Dionne; Stéphanie Camden; Lynne Moore; Nadine Allain-Boulé
Journal:  J Am Geriatr Soc       Date:  2013-10       Impact factor: 5.562

3.  Older patients presenting to a county hospital ED after a fall: missed opportunities for prevention.

Authors:  Miguel A Paniagua; Julie E Malphurs; Elizabeth A Phelan
Journal:  Am J Emerg Med       Date:  2006-07       Impact factor: 2.469

4.  EXercising with Computers in Later Life (EXCELL) - pilot and feasibility study of the acceptability of the Nintendo® WiiFit in community-dwelling fallers.

Authors:  Marie A Williams; Roy L Soiza; Alison McE Jenkinson; Alison Stewart
Journal:  BMC Res Notes       Date:  2010-09-13

5.  Drug Burden Index score and anticholinergic risk scale as predictors of readmission to the hospital.

Authors:  Rachel Dispennette; David Elliott; Lisa Nguyen; Rebecca Richmond
Journal:  Consult Pharm       Date:  2014-03

6.  Drug burden index score and functional decline in older people.

Authors:  Sarah N Hilmer; Donald E Mager; Eleanor M Simonsick; Shari M Ling; B Gwen Windham; Tamara B Harris; Ronald I Shorr; Douglas C Bauer; Darrell R Abernethy
Journal:  Am J Med       Date:  2009-12       Impact factor: 4.965

7.  Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: a randomized controlled trial.

Authors:  Hege Kersten; Espen Molden; Inga Kristin Tolo; Eva Skovlund; Knut Engedal; Torgeir Bruun Wyller
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-09-14       Impact factor: 6.053

8.  Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life.

Authors:  H V Curran; R Collins; S Fletcher; S C Y Kee; B Woods; S Iliffe
Journal:  Psychol Med       Date:  2003-10       Impact factor: 7.723

9.  Methodological challenges in determining longitudinal associations between anticholinergic drug use and incident cognitive decline.

Authors:  Mandavi Kashyap; Sylvie Belleville; Benoit H Mulsant; Sarah N Hilmer; Amelie Paquette; Le Mai Tu; Cara Tannenbaum
Journal:  J Am Geriatr Soc       Date:  2014-01-13       Impact factor: 5.562

Review 10.  Quantification of anticholinergic and sedative drug load with the Drug Burden Index: a review of outcomes and methodological quality of studies.

Authors:  Hans Wouters; Helene van der Meer; Katja Taxis
Journal:  Eur J Clin Pharmacol       Date:  2016-12-01       Impact factor: 2.953

View more
  2 in total

1.  Impact of Anticholinergic Medication Burden on Mobility and Falls in the Lifestyle Interventions for Elders (LIFE) Study.

Authors:  Patrick Squires; Marco Pahor; Todd M Manini; Scott Vouri; Joshua D Brown
Journal:  J Clin Med       Date:  2020-09-16       Impact factor: 4.241

Review 2.  Anticholinergic Drugs in Geriatric Psychopharmacology.

Authors:  Jorge López-Álvarez; Julia Sevilla-Llewellyn-Jones; Luis Agüera-Ortiz
Journal:  Front Neurosci       Date:  2019-12-06       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.